Journal article
Safety and efficacy of Tofacitnib in patients with active psoriatic arthritis: Interim analysis of OPAL balance, an open-label, long-term extension study
- Abstract:
-
Introduction:
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the interim safety, tolerability, and efficacy of tofacitinib in PsA patients in OPAL Balance, a 3-year, open-label, long-term extension study (data cut-off: August 2017; database not locked, data may change).
Methods:
Expand abstract
Eligible patients from two phase (P) 3 (P3) tofacitinib PsA studies (OPAL Broaden, NCT01877668; O...
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Springer Publisher's website
- Journal:
- Rheumatology and Therapy Journal website
- Publication date:
- 2020-06-06
- Acceptance date:
- 2020-04-21
- DOI:
- EISSN:
-
2198-6584
- ISSN:
-
2198-6584
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1102526
- Local pid:
- pubs:1102526
- Deposit date:
- 2020-04-30
Terms of use
- Copyright holder:
- Nash et al.
- Copyright date:
- 2020
- Rights statement:
- © The Author(s) 2020. This article is published under an open access license.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record